China (Mainland)
Diamondsupplier 
Lipid-lowering drugs Cetilistat CAS No:282526-98-1 CAS NO.282526-98-1
- FOB Price: USD: 1,000.00-1,000.00 /Kilogram Get Latest Price
- Min.Order: 25 Kilogram
- Payment Terms: T/T
- Available Specifications:
98.5%(0-100)Kilogram
- Product Details
Keywords
- Lipid-lowering drugs Cetilistat
- Cetilistat
- Cetilistat CAS No:282526-98-1
Quick Details
- ProName: Lipid-lowering drugs Cetilistat CAS No...
- CasNo: 282526-98-1
- Molecular Formula: C25H39NO3
- Appearance: A WHITE CRYSTALLINE POWDER
- Application: Lipid-lowering drugs
- DeliveryTime: 7 days
- PackAge: 25kg/drum
- Port: shanghai/hangzhou
- ProductionCapacity: 100 Kiloliter/Day
- Purity: 99%
- Storage: Normal
- Transportation: by air
- LimitNum: 25 Kilogram
- Valid Period: 2 years
- ASSAY: ≧99%
Superiority
Why is SINOWAY:
1) Specialized in pharmaceutical and healthcare industrial for 34 years.
2) ISO 9001:2015 & SGS audited supplier .
3) Accept various payment terms : T.T 30-60 days.
4) We have warehouse in USA with quickly shipment .
5) We can do different terms of FOB ,CIF/CIP ,DDP ...
Why choose us
1. best quality in your requirement
2. competitive price in china market
3. mature technical support
4. professional logistic support
5. full experience of large numbers containers loading in chinese sea port
6. fast shipment by reputed shipping line
7. packing with pallet as buyer's special request
8. best service after shipment with email !
9. cargoes together with container after-sales service available
10. full experience in export
11. raw materials from chinese origin
Details
Product Information
| Product Name | Cetilistat |
| CAS Number |
282526-98-1 |
| Molecular Formula | C25H39NO3 |
| Molecular Weight | 560.01401.58 |
| Purity | 99% |
| Appearance | White Powder |
| Melting Point | 72.0 to 76.0 °C |
| Boiling Point | 509.7±43.0 °C(Predicted) |
| EINECS Number | 1308068-626-2 |
| MOQ | 1 kg |
Cetilistat is a lipase inhibitor discovered by UK-based Alizyme Therapeutics Limited. Norgine acquired all rights to the product from Alizyme in October 2009. In 2003 Takeda acquired the rights for development and commercialisation for Japan. On September 20, 2013, the Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application (NDA) of Cetilistat (OBLEAN® Tablets 120mg) for the treatment of obesity with complications, which is the first therapy that controls lipid absorption approved in Japan for the treatment of obesity with complications.
